In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma

Biochemical Pharmacology

Volumn 77, Issue 2, 2009, Pages 228-237

  Jost, Marco M ^a   Lamerz, Jens ^a   Tammen, Harald ^a   Menzel, Christoph ^b   De Meester, Ingrid ^c   Lambeir, Anne Marie ^c   Augustyns, Koen ^c   Scharpé, Simon ^c   Zucht, Hans Dieter ^d   Rose, Horst ^a   Jürgens, Michael ^a   Schulz Knappe, Peter ^d   Budde, Petra ^d  

^a Digilab BioVisioN GmbH   (Germany)

^b QIAGEN GMBH   (Germany)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d Proteome Sciences R and D GmbH and Co KG   (Germany)

Author keywords

BRI peptide; Differential peptide display; Dipeptidyl peptidase 4; Peptidomics; Type 2 diabetes; Vildagliptin

Indexed keywords

AB 192; AMINO TERMINAL TELOPEPTIDE; AMYLOID PROTEIN; BIS(4 ACETAMIDOPHENYL) 1 PROLYLPYRROLIDINE 2 PHOSPHONATE; COLLAGEN TYPE 1; DIPEPTIDYL PEPTIDASE IV INHIBITOR; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; COLLAGEN METABOLISM; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PEPTIDOMICS; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; WISTAR RAT;

ADAMANTANE; AMYLOID; ANIMALS; ANTIGENS, CD26; COLLAGEN; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HEART VENTRICLES; HUMANS; KINETICS; NITRILES; PEPTIDE FRAGMENTS; PHOSPHONIC ACIDS; PROLINE; PYRROLIDINES; RATS; RATS, WISTAR; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUBSTRATE SPECIFICITY;

EID: 57249097041     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.09.032     Document Type: Article

References (43)

1. Balkan B., Kwasnik L., Miserendino R., Holst J.J., and Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42 (1999) 1324-1331
2. Burkey B.F., Li X., Bolognese L., Balkan B., Mone M., Russell M., et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 315 (2005) 688-695
3. Sudre B., Broqua P., White R.B., Ashworth D., Evans D.M., Haigh R., et al. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes 51 (2002) 1461-1469
4. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., et al. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV Inhibitor with antihyperglycemic properties. J Med Chem 46 (2003) 2774-2789
5. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., and Williams-Herman D.E. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 (2006) 2632-2637
6. Charbonnel B., Karasik A., Liu J., Wu M., and Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29 (2006) 2638-2643
7. Nauck M.A., Meininger G., Sheng D., Terranella L., and Stein P.P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9 (2007) 194-205
8. Rosenstock J., Baron M.A., Dejager S., Mills D., and Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30 (2007) 217-223
9. Schweizer A., Couturier A., Foley J.E., and Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med 24 (2007) 955-961
10. Ahren B., Gomis R., Standl E., Mills D., and Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2874-2880
11. Dejager S., Razac S., Foley J.E., and Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 39 (2007) 218-223
12. Green B.D., Flatt P.R., and Bailey C.J. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 3 (2006) 159-165
13. Richter B., Bandeira-Echtler E., Bergerhoff K., and Lerch C. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev (2008) CD006739
14. Brandt I., Lambeir A.M., Maes M.B., Scharpe S., and De Meester I. Peptide substrates of dipeptidyl peptidases. Adv Exp Med Biol 575 (2006) 3-18
15. Lambeir A.M., Durinx C., Scharpe S., and De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40 (2003) 209-294
16. Jost M., Budde P., Tammen H., and Schulz-Knappe P. Peptidomics based protease inhibitor profiling. In: Gänshirt D., Harms F., Rohmann S., and Schulz-Knappe P. (Eds). Peptidomics in drug development (2005), Editio Cantor, Aulendorf, Germany 65-73
17. Yates N.A., Deyanova E.G., Geissler W., Wiener M.C., Sachs J.R., Wong K.K., et al. Identification of peptidase substrates in human plasma by FTMS based differential mass spectrometry. Int J Mass Spectrom 259 (2007) 174-183
18. Belyaev A., Zhang X., Augustyns K., Lambeir A.M., De Meester I., Vedernikova I., et al. Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors. J Med Chem 42 (1999) 1041-1052
19. Tammen H., Schulte I., Hess R., Menzel C., Kellmann M., Mohring T., et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 5 (2005) 3414-3422
20. Lamerz J., Selle H., Scapozza L., Crameri R., Schulz-Knappe P., Mohring T., et al. Correlation-associated peptide networks of human cerebrospinal fluid. Proteomics 5 (2005) 2789-2798
21. de Meester I., Vanhoof G., Lambeir A.M., and Scharpe S. Use of immobilized adenosine deaminase (EC 3.5. 4. 4) for the rapid purification of native human CD26/dipeptidyl peptidase IV (EC 3. 4. 14. 5). J Immunol Methods 189 (1996) 99-105
22. Lambeir A.M., Proost P., Durinx C., Bal G., Senten K., Augustyns K., et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 276 (2001) 29839-29845
23. Tammen H. Specimen collection and handling: standardization of blood sample collection. Methods Mol Biol 428 (2008) 35-42
24. Vidal R., Frangione B., Rostagno A., Mead S., Revesz T., Plant G., et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 399 (1999) 776-781
25. Hopsu-Havu V.K., and Glenner G.G. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 7 (1966) 197-201
26. Hanski C., Huhle T., and Reutter W. Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen. Biol Chem Hoppe Seyler 366 (1985) 1169-1176
27. Bermpohl F., Loster K., Reutter W., and Baum O. Rat dipeptidyl peptidase IV (DPP IV) exhibits endopeptidase activity with specificity for denatured fibrillar collagens. Fed Euro Biochem Soc Lett 428 (1998) 152-156
28. Loster K., Zeilinger K., Schuppan D., and Reutter W. The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem Biophys Res Commun 217 (1995) 341-348
29. Amy Sang Q.-X., and Shi Y.-B. Collagenase 4. In: Barett A.J., Rawlings N.D., and Woessner J.F. (Eds). Handbook of proteolytic enzymes. 2nd ed. (2004), Elsevier Academic Press, London, San Diego 494-497
30. Cawston T.E. Collagenase 1. In: Barett A.J., Rawlings N.D., and Woessner J.F. (Eds). Handbook of proteolytic enzymes. 2nd ed. (2004), Elsevier Academic Press, London, San Diego 472-480
31. Henriet P., and Eeckhout Y. Collagenase 3. In: Barett A.J., Rawlings N.D., and Woessner J.F. (Eds). Handbook of proteolytic enzymes. 2nd ed. (2004), Elsevier Academic Press, London, San Diego 486-494
32. Tschesche H., Pieper M., and Wenzel H. Neutrophil collagenase. In: Barett A.J., Rawlings N.D., and Woessner J.F. (Eds). Handbook of proteolytic enzymes. 2nd ed. (2004), Elsevier Academic Press, London, San Diego 480-486
33. Tiruppathi C., Miyamoto Y., Ganapathy V., Roesel R.A., Whitford G.M., and Leibach F.H. Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains. J Biol Chem 265 (1990) 1476-1483
34. Tiruppathi C., Miyamoto Y., Ganapathy V., and Leibach F.H. Genetic evidence for role of DPP IV in intestinal hydrolysis and assimilation of prolyl peptides. Am J Physiol 265 (1993) G81-G89
35. Natori Y., Shindo N., and Natori Y. Proteinuria induced by anti-dipeptidyl peptidase IV (gp108); role of circulating and glomerular antigen. Clin Exp Immunol 95 (1994) 327-332
36. Thielitz A., Vetter R.W., Schultze B., Wrenger S., Simeoni L., Ansorge S., et al. Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. J Invest Dermatol 128 (2008) 855-866
37. Choi S.I., Vidal R., Frangione B., and Levy E. Axonal transport of British and Danish amyloid peptides via secretory vesicles. Fed Am Soc Exp Biol J 18 (2004) 373-375
38. Lambeir A.M., Proost P., Scharpe S., and De Meester I. A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro. Biochem Pharmacol 64 (2002) 1753-1756
39. Mentlein R., Gallwitz B., and Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214 (1993) 829-835
40. Lambeir A.M., Durinx C., Proost P., Van Damme J., Scharpe S., and De Meester I. Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. Fed Euro Biochem Soc Lett 507 (2001) 327-330
41. Kim J., Onstead L., Randle S., Price R., Smithson L., Zwizinski C., et al. Abeta40 inhibits amyloid deposition in vivo. J Neurosci 27 (2007) 627-633
42. Ghiso J.A., Holton J., Miravalle L., Calero M., Lashley T., Vidal R., et al. Systemic amyloid deposits in familial British dementia. J Biol Chem 276 (2001) 43909-43914
43. Scientific discussion (Sitagliptin). London: European Medicines Agency; 2007. p. 1-39.